Highest-materiality recent filing
Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042
USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.
Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026
API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track
Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028
Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes
Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.
First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC
Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M
Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.
Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer
FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.
Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025
CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.
Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer
First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
Allarity Therapeutics Q1 net loss $2.7M, cash $27.7M; stenoparib shows durable benefit
Net loss narrowed to $2.7M in Q1 2025 from $3.8M in Q1 2024; R&D expenses $1.4M, G&A $1.6M.
Allarity Therapeutics FY2024 net loss $24.5M; cash $20.9M at year-end, ~$25M at Q1 2025
Net loss $24.5M for 2024 vs $11.9M in 2023, driven by $9.7M intangible impairment and $2.5M SEC settlement.
5 of 15 patients stayed on therapy >4 months; 1 had confirmed complete response lasting >10 months.
Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty
Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.
Allarity announces VA-funded Phase 2 trial of stenoparib + temozolomide in recurrent SCLC
Phase 2 trial of stenoparib (dual PARP/Wnt inhibitor) plus temozolomide for recurrent SCLC, fully funded by VA.
Allarity Therapeutics announces dismissal of securities class action lawsuit against all defendants
Securities class action filed Sept 13, 2024, alleging false statements on Dovitinib NDA prospects dismissed with prejudice.
Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer
Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.
Allarity expands Phase 2 trial of stenoparib in advanced ovarian cancer; enrollment targets H1 2025
New Phase 2 protocol focuses on advanced, recurrent, platinum-resistant ovarian cancer patients.
Allarity Therapeutics reaches $2.5M SEC settlement over Dovitinib disclosure issues
Agreed in principle with SEC to pay $2.5M civil penalty and consent to cease-and-desist order for non-scienter securities law violations.
Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue
Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.
Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.
Allarity regains Nasdaq minimum bid price compliance after 20-day period
Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).
Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib
Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.
Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy
Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.
Allarity Therapeutics CFO resigns; appoints Alexander Epshinsky; boosts ATM capacity to $50M
Joan Brown resigned as CFO effective Sept 12, 2024; no disagreement with company.
Allarity Therapeutics corrects reverse stock split effective time to Sept 11, 2024
Certificate of Correction filed to set 1-for-30 reverse split effective 12:01 a.m. ET Sept 11, 2024.
Allarity Therapeutics files 1-for-30 reverse stock split, reduces authorized shares to 250M
Stockholders approved 1-for-30 reverse split at Sept 3 annual meeting; effective Sept 11, 2024.
On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.
On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.
On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.
On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.
On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.
On February 28, 2024, Allarity Therapeutics, Inc. (the “Company”) terminated the employment of Marie Foegh, M.D., the Company’s Chief Medical Officer. Ms. Foegh’s last day of employment was February 29, 2024.
On January 27, 2024, the Chairman of our Board of Directors (the “Board”), received email correspondence from Mr. James G. Cullem tendering his resignation (the “Resignation Email”) as a member of our Board.
On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.
On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.
On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.
Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.
On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material